At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
STTK Shattuck Labs, Inc.
Not Yet Opened 10-01 16:00:00 EDT
6.84
+0.02
+0.29%
盘后6.90
+0.06+0.88%
19:30 EDT
High7.29Low6.67Vol2.02M
Open6.95D1 Closing6.82Amplitude9.02%
Mkt Cap686.48MTradable Cap463.47MTotal Shares100.36M
T/O14.25MT/O Rate2.99%Tradable Shares67.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
MT Newswires Live  ·  10-01 21:25
Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating
Shattuck Labs (STTK) Receives a Buy from Leerink Partners
TIPRANKS  ·  10-01 20:36
Shattuck Labs (STTK) Receives a Buy from Leerink Partners
Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug
MT Newswires Live  ·  10-01 19:58
Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug
Shattuck Labs Names Shoba Ravichandran Senior Vice President, Clinical Development
Reuters  ·  10-01 19:00
Shattuck Labs Names Shoba Ravichandran Senior Vice President, Clinical Development
Shattuck Labs - Phase 2 Trial to Start in 2026; 16-Week Data Expected in H1 2028
THOMSON REUTERS  ·  10-01 19:00
Shattuck Labs - Phase 2 Trial to Start in 2026; 16-Week Data Expected in H1 2028
Shattuck Labs - Existing Cash Expected to Fund Operations into 2029
THOMSON REUTERS  ·  10-01 19:00
Shattuck Labs - Existing Cash Expected to Fund Operations into 2029
Shattuck Labs - to Initiate Phase 2 Trial of Sl-325 in Hidradenitis Suppurativa
THOMSON REUTERS  ·  10-01 19:00
Shattuck Labs - to Initiate Phase 2 Trial of Sl-325 in Hidradenitis Suppurativa
Shattuck Labs - Ind Submission for Phase 2 Trial Expected in October 2026
THOMSON REUTERS  ·  10-01 19:00
Shattuck Labs - Ind Submission for Phase 2 Trial Expected in October 2026
Shattuck Labs Announces Phase 2 Clinical Trial of Sl-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.d., as Senior Vice President, Clinical Development
THOMSON REUTERS  ·  10-01 19:00
Shattuck Labs Announces Phase 2 Clinical Trial of Sl-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.d., as Senior Vice President, Clinical Development
Pantginis Maintains Buy on Shattuck as Merck TL1A/DR3 Data De-Risk SL-325; Price Target Reiterated at $14
TIPRANKS  ·  10-01 00:45
Pantginis Maintains Buy on Shattuck as Merck TL1A/DR3 Data De-Risk SL-325; Price Target Reiterated at $14
Shattuck Labs management to meet with Piper Sandler
TIPRANKS  ·  09-24
Shattuck Labs management to meet with Piper Sandler
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
GlobeNewswire  ·  09-03
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target
MT Newswires Live  ·  08-24
Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target
Shattuck Labs Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $18
THOMSON REUTERS  ·  08-24
Shattuck Labs Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $18
Shattuck Labs initiated with a Strong Buy at Raymond James
TIPRANKS  ·  08-24
Shattuck Labs initiated with a Strong Buy at Raymond James
Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone
TIPRANKS  ·  08-13
Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone
Wedbush Reaffirms Their Buy Rating on Shattuck Labs (STTK)
TIPRANKS  ·  08-12
Wedbush Reaffirms Their Buy Rating on Shattuck Labs (STTK)
Shattuck Labs Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Shattuck Labs Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Sutro Biopharma Q2 Revenue Misses Estimates, Posts Wider Loss
Reuters  ·  08-12
Sutro Biopharma Q2 Revenue Misses Estimates, Posts Wider Loss
Erasca Q2 Net Loss Widens on Higher R&D Costs
Reuters  ·  08-12
Erasca Q2 Net Loss Widens on Higher R&D Costs

Introduction

Company Name.
Shattuck Labs, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Issue price:
--